Tech Center 1600 • Art Units: 1693
This examiner grants 37% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18276397 | SMALL MOLECULE INHIBITORS OF CD38 AS IMMUNOSUPPRESSANTS | Non-Final OA | OHIO STATE INNOVATION FOUNDATION |
| 18011832 | ANTIVIRAL COMPOUNDS AND METHODS OF USING THE SAME | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 18494749 | METHOD FOR MANUFACTURING CELLULOSE DERIVATIVE | Non-Final OA | SEIKO EPSON CORPORATION |
| 17960972 | BIOCOMPATIBLE SCAFFOLD AND USE THEREOF | Final Rejection | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED |
| 18002301 | COMPOSITIONS COMPRISING MYO-INOSITOL AND THEIR USE IN THE PREVENTION OF POST PARTUM HAEMORRHAGE (PPH) | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18028627 | OAT DERIVED BETA-(1-3)-(1-4)-GLUCAN PREPARATIONS AND THERE USE IN TREATING CANCER | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 17775213 | CERAMIDE ANALOG SACLAC MODULATES SPHINGOLIPID LEVELS AND MCL-1 SPLICING TO INDUCE APOPTOSIS IN ACUTE MYELOID LEUKEMIA | Non-Final OA | University of Virginia Patent Foundation |
| 18181016 | COMPOSITIONS AND METHODS FOR TREATING HYPERGLYCEMIA IN TYPE-2 DIABETES | Non-Final OA | The Board of Regents of the university of Oklahoma |
| 18252793 | ANTI-CANCER COMPOSITION CONTAINING AURANOFIN AND MERCAPTO COMPOUND AND USE THEREOF | Non-Final OA | SUN YAT-SEN UNIVERSITY |
| 17776760 | COMBINATION THERAPY WITH PROTEIN KINASE B ACTIVATION INHIBITOR TO TREAT CANCER | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17791754 | METHODS TO ALTER LATENCY IN EBV+ MALIGNANCIES | Final Rejection | Cornell University |
| 18261296 | IMPROVED METHOD FOR THE PREPARATION OF MICROCRYSTALLINE CELLULOSE | Non-Final OA | NUTRITION & BIOSCIENCES USA 1, LLC |
| 18279517 | THE USE OF EMPAGLIFLOZIN FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE | Non-Final OA | The Governors of the University of Alberta |
| 18557304 | Galactooligosaccharides for improving immune response | Non-Final OA | N.V. Nutricia |
| 18254401 | A METHOD OF TREATING FOOT ROT | Final Rejection | Intervet Inc. |
| 18269147 | HYALURONAN IS A DRIVER OF COVID-19 SEVERITY | Non-Final OA | The University of Manchester |
| 18564287 | NOVEL ISOFLAVONE COMPOUND | Non-Final OA | NABOCUL COSMETICS CO., LTD. |
| 18261592 | METHODS FOR PREVENTING VIRAL INFECTION | Non-Final OA | THERAPEUTIKOS, INC. |
| 18352220 | DINUCLEOTIDES AND THEIR USE IN TREATING CANCER | Non-Final OA | MAIA Biotechnology, Inc. |
| 18031447 | LIQUID COMPOSITION FOR USE IN THE PREVENTION OR REDUCTION OF SKIN IRRITATION, ALLERGY AND/OR AN INFECTIOUS DISEASE | Final Rejection | Medoderm GMBH |
| 18246213 | COMPOSITIONS COMPRISING A VEGETABLE CHONDROITIN OR AN ANALOGUE THEREOF AND THE USE THEREOF IN THE TREATMENT OF DISORDERS OF THE MUCOUS MEMBRANE OF THE ORAL, PHARYNGO-LARYNGEAL AND/OR GASTRO-OESOPHAGEAL TRACT | Non-Final OA | SOFAR SWISS SA |
| 18019580 | ANTIBACTERIAL COMPOSITIONS AND METHODS FOR FABRICATING THEREOF | Final Rejection | Harrow IP LLC |
| 18113370 | COMPOSITIONS AND METHODS FOR JOINT HEALTH | Non-Final OA | Unigen, Inc. |
| 17910779 | CROSS-LINKED MEDICATION FOR TREATMENT OF CORONAVIRAL INFECTION AND METHOD OF TREATMENT | Final Rejection | 1GLOBE HEALTH INSTITUTE, NANJING |
| 17782654 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND/OR TREATMENT OF DYSBIOSIS AND ANTIBACTERIAL ANTIDOTES FOR MICROBIOME-PROTECTION | Non-Final OA | EUROPEAN MOLECULAR BIOLOGY LABORATORY |
| 17624595 | PROCESS FOR PREPARATION OF EDOXABAN | Non-Final OA | Glenmark Life Sciences Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy